Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy

Pediatric Neurology
Sanjeev V KothareAgustin Legido

Abstract

The aim of this study was to evaluate the efficacy and safety of zonisamide monotherapy in a cohort of children and adolescents with various types of epilepsy. Retrospective review of charts of our institution from 2001 through 2004 identified 69 children (19 males and 50 females, mean age 13.2 years) with epilepsy on zonisamide monotherapy. Seizure count and side effect profile were maintained during therapy. Sixty-one percent had idiopathic generalized epilepsy, 4% symptomatic generalized epilepsy, and 35% partial-onset epilepsy. Zonisamide was the first-line and second-line monotherapy for 32% and 68% of patients, respectively. The mean duration of follow-up on treatment was 22 months (range 3-48 months). The overall efficacy of zonisamide was 75.4% (> or = 50% seizure frequency reduction: good responders). Sixty-seven percent of good responders became seizure-free. Seventy-nine percent of patients with partial epilepsy and 71% with generalized epilepsy were good responders, of whom 79% and 63% were free of seizure, respectively. Eighteen (26%) patients developed side effects: weight loss (9), cognitive impairment (3), sleepiness (3), dizziness (2), and decreased appetite (1). In seven patients (10%), zonisamide had to be di...Continue Reading

References

Jun 1, 1996·Seizure : the Journal of the British Epilepsy Association·M KitoK Watanabe
Nov 1, 1995·Epilepsy Research·M OkadaY Fukushima
Feb 5, 2000·The New England Journal of Medicine·P Kwan, M J Brodie
Nov 28, 2001·Neurology·E FaughtUNKNOWN Zonisamide 922 Trial Group
Apr 16, 2002·Journal of Child Neurology·Tracy A Glauser, John M Pellock
Jan 28, 2004·Neurology·Timothy E Lotze, Angus A Wilfong
Feb 6, 2004·JAMA : the Journal of the American Medical Association·Suzette M LaRoche, Sandra L Helmers
Oct 30, 2004·Seizure : the Journal of the British Epilepsy Association·Masakazu Seino
Jan 25, 2005·Pediatric Neurology·Angus A Wilfong

❮ Previous
Next ❯

Citations

Jan 5, 2008·Current Treatment Options in Neurology·Mazin Abdul, James J Riviello
Apr 16, 2011·Current Treatment Options in Neurology·Laura Mantoan, Matthew Walker
Sep 22, 2007·Annual Review of Medicine·B A Leeman, A J Cole
Mar 3, 2010·CNS Drugs·Dean P Sarco, Blaise F D Bourgeois
Feb 14, 2014·Advances in Therapy·Joanna H CoxAndrea E Cavanna
Oct 3, 2006·Expert Review of Neurotherapeutics·Alexis Arzimanoglou, Abdallah Rahbani
Feb 25, 2009·Expert Opinion on Pharmacotherapy·Paolo CuratoloCaterina Cerminara
Apr 25, 2008·Expert Opinion on Drug Metabolism & Toxicology·Sanjeev V Kothare, Joseph Kaleyias
Jul 1, 2008·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Ignacio ValenciaAgustín Legido
Oct 20, 2007·Epilepsy & Behavior : E&B·Sung-Pa ParkByung-In Lee
Jun 19, 2007·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Gerhard KlugerHans Holthausen
Oct 29, 2010·Developmental Disabilities Research Reviews·Dewi Frances T Depositario-Cabacar, Tesfaye-Getaneh Zelleke
Nov 28, 2009·Seizure : the Journal of the British Epilepsy Association·Hui Jeen TanRachel Kneen
Dec 14, 2011·Therapeutic Advances in Neurological Disorders·Clare M EddyAndrea E Cavanna
Jan 1, 2012·Journal of Central Nervous System Disease·Saima Kayani, Deepa Sirsi
Sep 1, 2018·Expert Opinion on Drug Safety·Romina MoaveroPaolo Curatolo
Apr 7, 2007·The Nurse Practitioner·Robin D Davenport, Nitin C Patel
Dec 1, 2007·Journal of Clinical Neurology·Sung-Pa ParkSoon-Hak Kwon
Jun 6, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Cyril V AboboDong Liang
Jan 7, 2011·Expert Opinion on Pharmacotherapy·Alberto VerrottiFrancesco Chiarelli

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Pediatric Neurology
Cesar C Santos, Teresa Brotherton
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society
Gerhard KlugerHans Holthausen
Seizure : the Journal of the British Epilepsy Association
Tohru SekiMariko Maezawa
© 2022 Meta ULC. All rights reserved